Drug intelligence / Profile preview

CK15

Development stage: Phase 1
Lead developer: Xinkai Medicine and Chemical Intermediates
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

CK15 is an investigational oral drug administered as soft capsules. It is currently undergoing clinical trials to evaluate its safety, pharmacokinetics, and pharmacodynamics in healthy subjects. The drug is being developed for the treatment of Stage 3, 4, and 5 chronic kidney disease secondary hyperparathyroidism.

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on CK15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CK15.

Explore the full profile